Project description
Better drug accessibility through innovative cell-based manufacture
Delivering life-saving medication fast and effectively is challenging from an engineering and manufacturing aspect. The II-LCA project changes manufacturing at cell level to make medicine more accessible. The project will fund the recruitment of an innovation associate in the Valitacell company, enhancing its capabilities in cell imaging, life sciences instrumentation and automation, and boosting the creation of new drugs and cellular therapeutics. The reduced cost of and improvement in manufacture will benefit a larger population in Europe, who will also have direct access to new therapies.
Objective
The successful recruitment and incorporation of an Innovation associate (IA), with expertise in live cell imaging, life sciences instrumentation and automation, into the Valitacell team is integral to the evolution of our technologies. The IA will dramatically enhance Valitacells capabilities in this space, strengthen existing collaborations, and generate further opportunities for future innovation. If successful, II-LCA will lead to the accelerated development of novel biological drugs and cellular therapeutics, for the treatment of diverse disease indications. European patients will benefit from increased access to targeted and innovative breakthrough therapies, through reduced cost of development and improved manufacturing paradigms.
Fields of science
Programme(s)
Funding Scheme
CSA - Coordination and support actionCoordinator
V94 DUBLIN 2
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.